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Abstract: Colorectal cancer (CRC) is influenced by infiltration of immune cell populations in the
tumor microenvironment. While elevated levels of cytotoxic T cells are associated with improved
prognosis, limited studies have reported associations between CD4+ T cells and disease outcomes.
We recently performed transcriptomic profiling and comparative analyses of sorted CD4+ and CD8+
tumor-infiltrating lymphocytes (TILs) from bulk tumors of CRC patients with varying disease stages.
In this study, we compared the transcriptomes of CD4+ with CD8+ TILs. Functional annotation
pathway analyses revealed the downregulation of inflammatory response-related genes, while T cell
activation and angiogenesis-related genes were upregulated in CD4+ TILs. The top 200 deregulated
genes in CD4+ TILs were aligned with the cancer genome atlas (TCGA) CRC dataset to identify a
unique gene signature associated with poor prognosis. Moreover, 69 upregulated and 20 downreg-
ulated genes showed similar trends of up/downregulation in the TCGA dataset and were used to
calculate “poor prognosis score” (ppScore), which was significantly associated with disease-specific
survival. High ppScore patients showed lower expression of Treg-, Th1-, and Th17-related genes,
and higher expression of Th2-related genes. Our data highlight the significance of T cells within the
TME and identify a unique candidate prognostic gene signature for CD4+ TILs in CRC patients.
Keywords: colorectal cancer; tumor microenvironment; T cells; transcriptomics
1. Introduction
Global cancer statistics have ranked colorectal cancer (CRC) as the fourth most com-
monly diagnosed cancer and associated it with high mortality in both sexes combined
(incidence; 6.1%, mortality; 9.2% of total cancer cases) [1]. The advent of novel therapeutic
approaches, primarily in the form of immunotherapy, and improved screening technologies
led to steady decrease in mortality rates of common cancers over the past few decades. How-
ever, these declines have slowed down or even halted for some cancers in recent years [2].
Therefore, there is a dire need to explore novel targets and biomarkers for cancer progression.
Besides the molecular basis of CRC development, which results from alterations
in genes that drive tumor formation, the in situ immune cell infiltrates in the tumor
microenvironment (TME) bear immense significance in disease prognosis. Tumor “immune
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editing” has been implicated in disease development and progression [3], and the tumor-
immune microenvironment (TIME) is widely recognized as responsible for dictating tumor
progression and response to therapy [4]. Effective destruction of cancer cells by tumor-
reactive T cells requires overcoming various immunosuppressive factors/mechanisms. Cell-
mediated immunosuppressive factors in the TME are primarily released by T regulatory
cells (Tregs) and myeloid-derived suppressor cells (MDSCs), both previously reported to
be expanded in the colorectal TME [5,6]. However, the relationship between Tregs and
tumor progression in CRC is less clear; some studies suggested that high infiltration of
FoxP3+ Tregs is associated with a favorable prognosis in CRC [7,8], while others reported
the association of Tregs with a poor prognosis and attributed it to Treg heterogeneity [9,10].
Moreover, while elevated levels of tumor-infiltrating cytotoxic T cells (CTLs) are associated
with improved prognosis and outcomes of CRC [11], limited studies have reported a
significant association between CD4+ T cell infiltration and survival; possibly attributing
it to the different subsets and heterogeneity of CD4+ T cell populations [12]. In addition,
“immunoscore” has been proposed as an additional tool for CRC prognosis [13]. Galon
et al., investigated CD3+ T cells and CD8+ CTLs in the center of a tumor and at the invasive
margin, and reported the immunological data as a more robust survival predictor than the
histopathological methods in clinical practice to segregate between CRC stages [14].
Molecular and cellular profiling of immune cell populations, specifically T cells, bear
great significance in understanding CRC development and progression. We have recently
performed transcriptomic profiling of sorted CD4+ [15] and CD8+ [16] tumor-infiltrating
lymphocytes (TILs) from bulk tumors of CRC patients with varying disease stages. We re-
ported downregulation of Th1-mediated immune response and cytotoxicity-mediated genes
but upregulation of epigenetic silencing-related genes in CD4+ TILs from CRC patients with
advanced stage disease [15]. Moreover, epigenetic regulation-related genes and response
to hypoxia were upregulated, while T cell/cell proliferation- and cell cycle-related genes
were downregulated in CD8+ TILs in advanced stage CRC patients [16]. These findings
highlighted the significance of CD4+ and CD8+ TILs in CRC patients during disease pro-
gression. In this study, we reanalyzed our data and performed comprehensive comparative
analyses of transcriptomes of CD4+ with CD8+ TILs from CRC patients (irrespective of
disease staging). Our data uncovered various genes and their associated pathways, which
are differentially expressed in CD4+ and CD8+ TILs from CRC patients. Importantly, we
found that genes associated with T cell co-stimulation were upregulated, while inflamma-
tory response-related genes were downregulated in CD4+ TILs, compared with CD8+ TILs,
among other genes/pathways. The clinical significance of our results was exploited via
alignment with the cancer genome atlas (TCGA) for colon and rectal cancer (COADREAD)
RNA-Seq dataset, which enabled us to identify a unique gene signature of CD4+ TILs
associated with decreased disease-specific survival (DSS) in data from 512 CRC patients. We
referred to this gene signature as a “poor prognostic” (pp) gene signature and scored our
patient cohort based on its expression. We found that patients with a high ppScore showed
lower CD4+ TILs than those with a low ppScore. Moreover, comparative analyses of their
transcriptomes revealed impaired immune responses and downregulation of important
pathways, such as DNA repair, in high ppScore patients. Thus, our data show the potential
candidacy of a unique gene signature associated with poor DSS in CRC patients.
2. Materials and Methods
2.1. Study Design
Tumor tissue specimens from 18 CRC patients were used to sort pure CD4+ and
CD8+ TILs. Libraries were generated from sorted cells for performing RNA-Seq. Various
bioinformatics tools were utilized for analyses and visualization of RNA-Seq data. The raw
data used in this study were generated previously in the same patient cohort [15,16] but
were analyzed herein to uncover novel information. The study design has been clearly
presented in [16] and summarized below.
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2.2. Sample Collection and Storage
Tumor tissue (TT) specimens were collected from 18 treatment-naïve CRC patients,
who undertook surgical tumor resection at Hamad Medical Corporation, Doha, Qatar.
The clinical and pathological features of all participating patients are listed in Table 1.
Written informed consents were collected from patients prior to sample collection. This
study received ethical approvals from the Institutional Review Boards at Hamad Medical
Corporation, Doha, Qatar (protocol no. MRC-02-18-012) and the Qatar Biomedical Research
Institute, Doha, Qatar (protocol no. 2017-006).
Table 1. Clinical and pathological features of the study cohort.
CRC Patients
Number 18








G2 (Moderately differentiated) 17
G3 (Poorly differentiated) 1
Lymphovascular invasion 2







* Possibility of Lynch syndrome.
TT specimens were cut into smaller sections and stored in freezing medium [40%
RPMI-1640 medium (Life Technologies, New York, NY, USA), 50% fetal calf serum (FCS; Hy-
clone, GE Healthcare Life Sciences, Logan, UT, USA), and 10% dimethylsulphoxide (DMSO;
Sigma-Aldrich, St. Louis, MO, USA)] to be used in batches for succeeding investigations,
as previously described [16,17].
2.3. Dissociation of Tissues
Bulk TT specimens were mechanically dissociated to prepare cell suspensions, as
previously described [16,17]. Briefly, frozen TT specimens were washed with phosphate-
buffered saline (PBS) and a surgical scalpel was used to cut TT into small pieces (~2–4 mm).
A GentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) was used to
perform cell dissociation without utilizing proteolytic enzymes. Resulting cell suspension
was passed through a cell strainer (100 µM) to remove debris and cell aggregates, and
washed multiple times with PBS prior to cell sorting.
2.4. Cell Sorting
Single cell suspensions from TT specimens were resuspended in 100 µL of flow cy-
tometry staining buffer (PBS with 1% FCS and 0.1% sodium azide). An FcR Blocking
Reagent (Miltenyi Biotec) was used to block Fc receptors (FcR) and a 7-AAD viability dye
(eBioscience, San Diego, CA, USA) was used to gate live cells. Cells were stained with
surface antibodies against CD3-allophycocyanin-Cy7 (clone SK7, BD Pharmingen, San Jose,
CA, USA), CD4-phycoerythrin (clone RPA-T4, BD Pharmingen), and CD8-fluorescein isoth-
iocyanate (clone RPA-T8; BD Pharmingen). Cells were washed twice with flow cytometry
staining buffer prior to re-suspension in Pre-Sort buffer (BD Biosciences, Oxford, UK). A
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BD FACSAria III SORP cell sorter on BD FACSDiva software (BD Biosciences) was used
for sorting pure CD4+ (7AAD−CD3+CD4+CD8−), and CD8+ (7AAD−CD3+CD4−CD8+)
TILs. Relevant procedures were followed to ensure minimum sorter-induced cell stress
(SICS), as previously described [18]. Flow cytometric analyses were performed on FlowJo
V10 software (FlowJo, Ashland, OH, USA).
2.5. RNA Isolation and Amplification
RNA was isolated from sorted, pure CD4+ and CD8+ TILs from 18 CRC patients using
an RNA/DNA/protein purification Plus Micro Kit (Norgen Bioteck Corporation, Thorold,
Ontario, Canada) by following manufacturer’s protocol. RNA was amplified using a 5X
MessageAmp™ II aRNA Amplification Kit (Invitrogen, Carlsbad, CA, USA) by following
the manufacturer’s protocol. Concentrations of RNA were determined using Qubit RNA
HS or Broad Range Assay Kits (Invitrogen, Carlsbad, CA, USA).
2.6. Library Preparation
cDNA libraries were generated from amplified RNA using an Exome TruSeq Stranded
mRNA Library Prep Kit (illumina, San Diego, CA, USA) by following the manufacturer’s
protocol, and as previously described [19]. Quality-passed libraries were processed for
clustering using a TruSeq PE Cluster Kit v3-cBot-HS (illumina). The clustered samples were
sequenced on an illumina HiSeq 4000 platform using a HiSeq 3000/4000 SBS kit (illumina).
2.7. RNA-Sequencing Data Processing and Analyses
RNA-Seq data were analyzed and illustrated using multiple bioinformatics tools. Pair
end reads were quality-trimmed and aligned to the hg19 human reference genome in CLC
Genomics Workbench 12 (Qiagen), as previously described [19]. The expression levels of
transcripts were measured as TPM (Transcripts Per Million) mapped reads. Abundance
data were successively subjected to differential gene expression analyses. The Z-scores were
calculated from TPM values, as previously described [20], and used to generate heatmaps.
Volcano plots were generated using OrignPro 2020 software (OriginLab Corpora-
tion, Northampton, MA, USA) with log2 FC > 2 and p value cutoff < 0.05. The Gene
Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
way enrichment analyses of differentially expressed genes (DEGs) were performed by
the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool, as
previously described [21].
2.8. Data Alignment with the Cancer Genome Atlas (TCGA) Colorectal Cancer
The top 100 upregulated genes and 100 downregulated genes from CD4+ and CD8+
TILs comparison was selected for analysis in a TCGA CRC dataset. Upregulated and
downregulated genes aligned with TCGA data were used to identify the “poor prognosis
gene signature score”. The ppScore was calculated as the ratio of the average expression
of the aligned upregulated genes to the average of the aligned downregulated genes.
The percentile calculations for the ppScore were performed to determine CRC patients
with a high ppScore and a low ppScore. Therefore, the poor prognosis gene signature
was identified from data of our cohort and its prognostic significance was confirmed by
TCGA datasets (512 CRC patients). The survival and phenotype data were obtained from
TCGA database to plot Kaplan–Meier survival curve and calculate log-rank p values using
Graphpad Prism 8. Multivariate analyses/Cox proportional-hazard model were performed
using EZR (Easy R) statistical software. Chi-squared χ2 test was used to determine the
statistical significance of the distribution of CRC patients across different disease stages.
2.9. TCGA Immune Estimations
Gene expression of 69 upregulated and 20 downregulated genes, which are included in
the gene signature, were downloaded from the UCSC Xena platform (http://xena.ucsc.edu/)
for 512 CRC (COAD) patient cohort. The immune infiltration data (CD4+ and CD8+ TILs)
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for the aforementioned patients were obtained from CIBERSORT immune fractions (https:
//gdc.cancer.gov/). Correlation analyses between the gene expression and CD4/CD8 TILs
fraction were performed using a regression-based method. The obtained correlation coefficients
were plotted as heatmaps. The p value < 0.05 is considered as statistically significant.
3. Results
3.1. Comparing Transcriptomes of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Colorectal
Cancer Patients
The presence of TILs in CRC patients has been associated with improved clinical
outcomes [22,23]. However, heterogeneity of TILs contributes to both pro- and antitumor
roles [24]. To understand the differences between roles of T cells in the colorectal TME, we
performed differential gene expression analyses for transcriptomes of sorted, pure CD4+
and CD8+ TILs. We used CD8+ TILs as controls due to their widely accepted antitumor
roles [25] and compared with the transcriptome of CD4+ TILs due to their dual roles in
tumor progression. We found 4008 differentially expressed genes (DEGs) between CD4+
and CD8+ TILs (log2 FC ≥ 2 and p value cutoff ≤ 0.05). A total of 2000 genes were
upregulated, while 2008 genes were downregulated in CD4+ TILs (Figure 1A). Of note,
genes known to be expressed in CD4+ or CD8+ T cells were utilized as controls to confirm
the purity of the analyzed T cell subsets.




Figure 1. Differential gene expression analyses of CD4+ and CD8+ TILs. Transcriptomic profiling and 
differential gene expression analyses were performed from FACS sorted pure CD4+ and CD8+ TILs 
from 18 CRC patients. Volcano plot shows the significantly upregulated (red; 2000 genes) and 
downregulated (green; 2008 genes) with p value <0.05 and FC>1 in CD4+ TILs, compared with CD8+ 
TILs (A). Volcano plot shows the deregulation of selected genes in CD4+ vs. CD8+ TILs and repre-
sentative heatmap of Z-score for significantly downregulated or upregulated genes in CD4+ TILs 
and CD8+ TILs. Scatter plots show the Log10 TPM of selected genes ± SEM in CD4+ TILs and CD8+ 
TILs (B). Functional annotations of significantly downregulated and upregulated genes (with p < 
0.05) were analyzed by DAVID web-based tool. Bars show the fold enrichment of pathways that 
were significantly downregulated or upregulated in CD4+ TILs from CD4+ TILs vs. CD8+ TILs (C). 
Heatmaps for selected upregulated and downregulated pathways and show the Z-score for genes 
that were differentially expressed in CD4+ TILs vs. CD8+ TILs (D). 
3.2. Differential Expression of T Cell Related Genes 
We then investigated DEGs between CD4+ and CD8+ TILs, focusing on T cell related 
genes (Figure 1B, Supplementary Materials Table S1). We found that IL4, IL5, IL17, CCR6, 
and RORC were upregulated, while ZEB2, IL91R and ITGAE were downregulated in CD4+ 
TILs. Importantly, immune checkpoint genes, including CTLA4 and ICOS, were upregu-
lated, while HAVCR2 (gene encodes TIM-3) and LAG3 were downregulated in CD4+ TILs, 
with no significant changes recorded in PDCD1 (gene encodes PD-1) expression between 
CD4+ and CD8+ TILs. Moreover, we found that TOX gene, representing a member of the 
thymocyte selection-associated high mobility group box protein (TOX) family implicated 
in T cell exhaustion [26], was downregulated in CD4+ TILs, compared to CD8+ TILs (Figure 
1B). However, there was no significant difference in the expression of TOX3 (TNRC9) be-
tween CD4+ TILs and CD8+ TILs (Figure 1B). In order to validate the association between 
gene signature and protein expression on TILs, we investigated the expression levels of 
selected dysregulated genes on CD4+ and CD8+ TILs from six patients out of our patient 
cohort (Supplementary Materials Figure S1). These genes include immune checkpoints; 
HAVCR2 (gene for TIM-3), ICOS and LAG3. In agreement with the transcriptomic data, 
we found that TIM-3 protein was expressed at higher levels on CD8+ TILs compared to 
CD4+ TILs (p = 0.035, Supplementary Materials Figure S1A). LAG-3 protein levels were 













-20 0 20-60 -40
Fold Change (P<0.05)





(+) Regulation of granzyme B production
(+) Regulation of (IFN-γ) production
(NK) cell mediated cytotoxicity
DNA repair
(-) Regulation of map kinase activity
Cellular response to TNF
Cell surface receptor signaling pathway




(+) Regulation Of ERK1 And ERK2 Cascade
Chemokine-mediated signaling pathway
Cellular response to (IFN-γ) 
(+) Regulation of il-2 production
(+) Regulation of programmed cell death
Th17 cell differentiation
T Cell activation
(-) Regulation of IL-4 production
(-) Regulation Of IL-6 production
(+) Regulation of activated t cell proliferation








TNRC9 (TOX3) MMP9 (MMP9)
LRRC32 (GARP) HAVCR2 (TIM-3)









































































































































































Figure 1. Differential gene expression analyses of CD4+ and CD8+ TIL . Transcriptomic profiling d differential gene
expression analyses were per o med from FACS orted pure CD4+ and CD8+ TILs from 18 CRC patients. Volcano plot
shows the significantly upregulated (red; 2000 genes) and d wnregulated (green; 2008 genes) with p value < 0.05 and FC > 1
in CD4+ TILs, compared with CD8+ TILs (A). Volcano plot shows the deregulation of selected genes in CD4+ vs. CD8+ TILs
and representative heatmap of Z-score for significantly downregulated or upregulated genes in CD4+ TILs and CD8+ TILs.
Scatter plots show the Log10 TPM of selected genes ± SEM in CD4+ TILs and CD8+ TILs (B). Functional annotations of
significantly downregulated and upregulated genes (with p < 0.05) were analyzed by DAVID web-based tool. Bars show
the fold enrichment of pathways that were significantly downregulated or upregulated in CD4+ TILs from CD4+ TILs vs.
CD8+ TILs (C). Heatmaps for selected upregulated and downregulated pathways and show the Z-score for genes that were
differentially expressed in CD4+ TIL vs. CD8+ TILs (D).
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3.2. Differential Expression of T Cell Related Genes
We then investigated DEGs between CD4+ and CD8+ TILs, focusing on T cell re-
lated genes (Figure 1B, Supplementary Materials Table S1). We found that IL4, IL5, IL17,
CCR6, and RORC were upregulated, while ZEB2, IL91R and ITGAE were downregulated
in CD4+ TILs. Importantly, immune checkpoint genes, including CTLA4 and ICOS, were
upregulated, while HAVCR2 (gene encodes TIM-3) and LAG3 were downregulated in
CD4+ TILs, with no significant changes recorded in PDCD1 (gene encodes PD-1) expres-
sion between CD4+ and CD8+ TILs. Moreover, we found that TOX gene, representing
a member of the thymocyte selection-associated high mobility group box protein (TOX)
family implicated in T cell exhaustion [26], was downregulated in CD4+ TILs, compared
to CD8+ TILs (Figure 1B). However, there was no significant difference in the expression
of TOX3 (TNRC9) between CD4+ TILs and CD8+ TILs (Figure 1B). In order to validate
the association between gene signature and protein expression on TILs, we investigated
the expression levels of selected dysregulated genes on CD4+ and CD8+ TILs from six
patients out of our patient cohort (Supplementary Materials Figure S1). These genes include
immune checkpoints; HAVCR2 (gene for TIM-3), ICOS and LAG3. In agreement with the
transcriptomic data, we found that TIM-3 protein was expressed at higher levels on CD8+
TILs compared to CD4+ TILs (p = 0.035, Supplementary Materials Figure S1A). LAG-3
protein levels were also higher on CD8+ TILs compared to CD4+ TILs, but did not show
statistical significance (Supplementary Materials Figure S1B). In contrast, ICOS protein was
expressed at higher levels on CD4+ TILs (p = 0.005, Supplementary Materials Figure S1C).
3.3. Functional Pathways Enriched in CD4+ TILs Compared to CD8+ TILs
To identify the functional pathways of DEGs from CD4+ vs. CD8+ TILs comparison,
we performed gene ontology (BP) and KEGG pathway analyses using the DAVID platform.
We found that genes involved in the regulation of IFNγ/granzyme B production, IL-2
production, response to hypoxia, chemotaxis, and inflammatory response were downreg-
ulated in CD4+ compared to CD8+ TILs (Figure 1C,D). In contrast, T cell co-stimulation-,
activation-, proliferation-, Th17 differentiation-, IL-4/IL-6 production- and angiogenesis-
related genes were upregulated in CD4+ compared to CD8+ TILs (Figure 1C,D). The up-
regulated genes include ICOS, BTLA, ANG, IL2RA, RORC, CD83, and MALT1 (Figure 1D),
while downregulated genes include CCL3, CCL5, HAVCR2, TNFSF4, IFNL1, CD81, and
PRDX5 (Figure 1D).
3.4. Aligning Gene Profile of CD4+ TILs from CRC Patients with TCGA Revealed a Distinct Gene
Signature Associated with Poor Disease-Specific Survival
The top 100 upregulated and downregulated genes from CD4+ TILs vs. CD8+ TILs
were annotated on TCGA COADREAD RNA-Seq dataset to identify ppScore. Of these
100 upregulated genes, 98 genes were annotated in TCGA CRC RNA-Seq dataset, of
which 69 genes (70.4%) had higher expression in patients with poorer DSS. For the
100 downregulated genes, 96 genes were annotated in TCGA dataset, of which 20 genes
(20.8%) had lower expression in patients with poorer DSS. The selected 69 upregulated
and 20 downregulated genes were used as the “poorer prognosis gene signature score”
(Supplementary Materials Table S2). The ppScore was calculated as the ratio of the average
expression of the 69 upregulated genes to the average of the 20 downregulated genes.
The percentile calculations for the ppScore were performed to determine CRC patients
with a high ppScore (top 50%) or a low ppScore (bottom 50%). Patients in TCGA dataset
were classified into two groups, either with a low (n = 241) or a high ppScore (n = 243).
Interestingly, we found that patients with a high ppScore had significantly poorer DSS,
compared to those with a low ppScore (log-rank p = 0.0012, Figure 2A). Moreover, multi-
variate analyses using Cox proportional-hazard model showed that our identified ppScore
was an independent prognostic factor for DSS, even in the presence of disease stage as
an indicator (p = 0.037, HR ± 95%, Figure 2B). Patients with a high ppScore were more
likely to have advanced disease stages (χ2 P = 0.042, Figure 2C). Taken together, the TCGA
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analyses support that the identified ppScore could predict DSS in CRC patients. Next, we
classified our patient cohort into two groups based on the percentile cutoff of the threshold
value; high ppScore (n = 9) and low ppScore (n = 9) patients (Supplementary Materials
Table S3). Gene expression analyses showed that 958 genes were differentially expressed in
high ppScore patients with FDR cutoff < 0.01, of which 441 were upregulated and 517 were
downregulated (Figure 2D).




Figure 2. Evaluation of ppScore in TGCA COADREAD dataset. Kaplan–Meier curves for disease-
specific survival were compared between patients with high (top 50%) and low (bottom 50%) 
ppScores. The number (n) of patients in each of the ppScore groups and the log-rank p value from 
Mantel–Cox test are indicated (A). Multivariate analyses using Cox proportional-hazard model 
evaluating the prognostic indication for the ppScore, disease stage (Stages I, II, III and IV), anatomic 
locations (7 different locations), residual disease (yes, no), gender (male, female) and age (<55, 55–
64, 65–74, >74 years of age), and for disease-specific survival (B). Data shown is the hazard ratio 
(HR) ± 95% confidence interval (CI) and the multivariate p values are indicated. Distribution of pa-
tients with a high and low ppScore across different stages using Chi-squared (χ2) test (Stages I, II, 
III and IV) (C). Our patient cohort was classified into two groups: high ppScore and low ppScore, 
and differential analyses were performed. Hierarchical clustering shows high ppScore and low 
ppScore (9 patients each) on differentially expressed transcripts in CD4+ TILs. Expression level is 
depicted as a color code and each column represents a sample and each row represents a transcript 
(D). 
Next, we correlated the expression of genes included in the signature cluster with 
CD4+ and CD8+ infiltrated from the deconvoluted COAD-TCGA dataset. We have calcu-
lated the correlation coefficient, “R”, and their significance, “p value”, to identify a plau-
sible correlation of gene expression with the CD4 and CD8 fraction. Interestingly, we 
found that the vast majority of genes showed very weak correlations in either T cell subset 
with statistically non-significant p values (Figure 3A,B). From the upregulated panel, only 
2.8% and 15.9% genes showed a statistically significant correlation with CD4+ and CD8+ 
TILS, respectively (p < 0.05, Figure 3A,B). Furthermore, in the downregulated panel, none 
of the genes from CD4+ TILs, while only 5% from CD8+ TILs, showed statistical signifi-
cance (p < 0.05, Figure 3A,B). Notably, none of the genes showed strong positive or nega-
tive correlation coefficient with gene expression. Altogether, these data confirm that the 
identified gene signature is an independent factor and has no potential correlation with 
CD4+ or CD8+ TILs fraction. 
Figure 2. Evaluation of ppScore in TGCA COADREAD dataset. Kaplan–Meier curves for disease-
specific survival were compared between patients with high (top 50%) and low (bottom 50%)
ppScores. The number (n) of patients in each of the ppScore groups and the log-rank p value from
Mantel–Cox test ar indicated (A). Multivariate analyses using Cox pr porti nal-hazard mo el
evaluating the prognostic ind ation for the ppScore, disease t g (Stages I, II, III and V), anatomic
locations (7 different locati ns), residual disease (y s, no), gender (male, female) and age (<5 ,
55–64, 65–74, >74 years of age), and for disease-specific survival (B). Data shown is the hazard ratio
(HR) ± 95% confidence interval (CI) and the multivariate p values are indicated. Distribution of
patients with a high and low ppScore across different stages using Chi-squared (χ2) test (Stages I, II,
III and IV) (C). Our patient cohort was classified into two groups: high ppScore and low ppScore, and
differential analyses were performed. Hierarchical clustering shows high ppScore and low ppScore
(9 patients each) on differentially expressed transcripts in CD4+ TILs. Expression level is depicted as
a color code and each column represents a sample and each row represents a transcript (D).
Next, we correlated the expression of genes included in the signature cluster with CD4+
and CD8+ infiltrated from the deconvoluted COAD-TCGA dataset. We have calculated
the correlation coefficient, “R”, and their significance, “p value”, to identify a plausible
correlation of gene expression with the CD4 and CD8 fraction. Interestingly, we found
that the vast majority of genes showed very weak correlations in either T cell subset
with statistically non-significant p values (Figure 3A,B). From the upregulated panel,
only 2.8% and 15.9% genes showed a statistically significant correlation with CD4+ and
CD8+ TILS, respectively (p < 0.05, Figure 3A,B). Furthermore, in the downregulated panel,
none of the genes from CD4+ TILs, while only 5% from CD8+ TILs, showed statistical
significance (p < 0.05, Figure 3A,B). Notably, none of the genes showed strong positive or
negative correlation coefficient with gene expression. Altogether, these data confirm that
the identified gene signature is an independent factor and has no potential correlation with
CD4+ or CD8+ TILs fraction.
Vaccines 2021, 9, 334 8 of 15Vaccines 2021, 9, x  9 of 16  
 
 
Figure 3. T cell infiltration in high and low ppScore CRC patients. CD4+/CD8+ TILs’ distribution 
data were deconvoluted from TCGA datasets of 512 CRC patients. Correlation analyses were then 
performed on the identified gene signature from our data and T cell infiltration data from TCGA, 
using a regression-based method. The correlation coefficient R values were plotted as heatmaps, 
where the significantly correlated genes (p < 0.05) were marked in black boxes (A). The bar plots 
show the percentages of significant genes from downregulated and upregulated gene signature 
panel in CD4+ and CD8+ TILs (B). 
3.5. Differences in Tumor-Infiltrating T Cells between CRC Patients with High and Low ppScore 
Next, we investigated the density of T cell infiltration in high and low ppScore pa-
tients in our cohort. We found that the levels of CD3+ TILs were less in patients with a 
high ppScore than a low ppScore, although it did not reach statistical significance, plausi-
bly due to small sample size (Figure 4A). Interestingly, there was a significant reduction 
in levels of CD3+CD4+ TILs in patients with a high ppScore compared to a low ppScore. 
Moreover, there was no difference in the levels of CD3+CD8+ TILs between high and low 
ppScore patients (Figure 4A). These results prompted us to investigate the transcriptomes 
of CD4+ TILs from patients from the two patient groups to identify the potential T cell 
subtype(s). In this pursuit, we investigated differences in the expression levels of various 
Treg/Th1/Th2 and Th17 signature genes between patients with a high vs. a low ppScore 
(Figure 4B). Interestingly, we found that Treg signature genes, including CCR8, FOXP3, 
CD40LG, IL2RA, CCR6, CTLA4, ICOS, IL7R, IKZF2, PTPRC, LAG3, and ITGAE; Th1 signa-
ture genes, including IFNG, TBX21, IRF8, CCL5, and PRF1; and Th17 signature genes, in-
cluding RORC, HIFIA, IL17F, IL17A, and KLRB1 were significantly downregulated in 
CD4+ TILs in patients with a high ppScore compared with low ppScore patients. On the 
other hand, Th2 signature genes, including GATA3, IL4 and IKZF1, were significantly up-
regulated in CD4+ TILs in patients with a high ppScore, compared with low ppScore pa-
tients (Figure 4B). 
Figure 3. T cell infiltration in high and low ppScore CRC patients. CD4+/CD8+ TILs’ distribution
data were deconvoluted from TCGA datasets of 512 CRC patients. Correlation analyses were then
performed on the identified gene signature from our data and T cell infiltration data from TCGA,
using a regression-based method. The correlation coefficient R values were plotted as heatmaps,
where the significantly correlated genes (p < 0.05) were marked in black boxes (A). The bar plots
show the percentages of significant genes from downregulated and upregulated gene signature panel
in CD4+ and CD8+ TILs (B).
3.5. Differences in Tumor-Infiltrating T Cells between CRC Patients with High and Low ppScore
Next, we investigated the density of T cell infiltration in high and low ppScore patients
in our cohort. We found that the levels of CD3+ TILs were less in patients with a high
ppScore than a low ppScore, alt ough it did not reach statistical sig ificance, plausibly due
to small sample size (Figure 4A). Interestingly, there was a significant reduction in levels of
CD3+CD4+ TILs in patients with a high ppScore compared to a low ppScore. Moreover,
there was no difference in the levels of CD3+CD8+ TILs between high and low ppScore
patients (Figure 4A). These results prompted us to investigate the transcriptomes of CD4+
TILs from patients from the two patient groups to identify the potential T cell subtype(s). In
this pursuit, w inve tigated diff rences in the expre sion levels of various Treg/Th1/Th2
and Th17 signature genes between patients with a high vs. a low ppScore (Figure 4B).
Interestingly, we found that Treg signature genes, including CCR8, FOXP3, CD40LG,
IL2RA, CCR6, CTLA4, ICOS, IL7R, IKZF2, PTPRC, LAG3, and ITGAE; Th1 signature genes,
including IFNG, TBX21, IRF8, CCL5, and PRF1; and Th17 signature genes, including RORC,
HIFIA, IL17F, IL17A, and KLRB1 were significantly dow regulated in CD4+ TILs in patients
with a high ppScore compared with low ppScore patients. On the other hand, Th2 signature
genes, including GATA3, IL4 and IKZF1, were significantly upregulated in CD4+ TILs in
patients with a high ppScore, compared with low ppScore patients (Figure 4B).
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Figure 4. Characterization of high ppScore and low ppScore CRC patients. The 18 patients’ cohort was classified into
two groups; high ppScore and low ppScore, as mentioned before. Scatter plots show the percentage of CD3+, CD4+ and
CD8+ TILs ± SEM in high and low ppScore patients (A). Heatmaps show the Z-score of Treg- Th1-, Th2- and Th17- related
genes in CD4+ TILs from high and low ppScore patients (B). Functional annotations of significantly downregulated and
upregulated genes (with p < 0.05) were analyzed by a DAVID web-based tool. Bars show t e fold enrichment of pathways
that were significantly downregulated or upregulated in CD4+ TILs from high ppScore vs. low ppScore patients. Heatmaps
for selected upregulated and do nregulated pathways show the Z-score for genes that were differentially expressed in
CD4+ TILs from high ppScore vs. low ppScore patients (C).
3.6. Differentially Expressed Genes and Associated Pathways between CRC Patients with High and
Low ppScore
We then identified potential pathways, which were significantly deregulated in CD4+
TILs, from CRC patients with s high ppScore compared with low ppScore patients. Inter-
estingly, we found that genes related to immune/inflammatory response, DNA replica-
tion/repair, T cell chemotaxis/stimulation, MHC class II presentation, response to IFNγ,
and granzyme B production/T cell mediated cytotoxicity were all downregulated in CD4+
TILs from patients with a high ppScore compared to patients with low ppScores (Figure 4C).
In contrast, protein phosphorylation-, NF-κB activity-, IL-1-mediated signaling- and nega-
tive regulation of apoptosis-related genes were upregulated in patients with high ppScores
(Figure 4C). The upregulated genes in high ppScore patients included IGF1R, IFNGR1,
FLT4, PRNP and TWIST1, among others (Figure 4C), while downregulated genes included
HLA-DQB1, CCL3, CCL4, IL22, CXCR3 and CXCL10, among others (Figure 4C). These
results reflect the potential impaired activity of CD4+ TILs in patients with high ppScores
and reiterate the significance of the identified gene signature, which affects pathways that
could potentially contribute to poor prognosis via aberrant antitumor immune responses.
4. Discussion
Our data reiterate that CD4+ and CD8+ TILs comprise heterogenous populations,
perform distinct roles, and affect unique pathways which dictate CRC tumor progression.
However, the proper functionality of T cells is of paramount significance in antitumor
immunity, and it has been shown that the activities of tumor-infiltrating T cells are dif-
ferentially affected by the TME [27]. The functional impairment of T cells can be evident
from the exp ssion levels of immune checkpoints and T c ll exhaustion markers [28]. We
found hat the majority of immune checkpoint genes were overexpressed in CD8+ TILs
compa ed to CD4+ TILs, potent ally sugg sting T cell exha stion and dysfunction of CTLs
in the TME of CRC pati nts. Importantly, the downr gulation of genes elated to T cell acti-
vation/proliferation and co-stimulation in CD8+ TILs, compared to CD4+ TILs in our data,
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supported these findings. In addition, identification of such gene signatures associated
with T cell dysfunction can also serve as predictive biomarkers for therapy. Jiang et al.,
showed that gene signatures related to T cell dysfunction and exclusion from the TME can
predict a therapy response to immune checkpoint inhibitors, anti-PD-1 and anti-CTLA4
mAbs, in melanoma patients [29]. Gene signatures could be utilized as tools to distinguish
potential cancer patients who could respond better to immunotherapies, including immune
checkpoint inhibitors, based on the characterization of their tumor nature, “hot tumors”,
i.e., T cell-inflamed tumors vs. “cold tumors”, i.e., T cell desert or noninflamed tumors in
cancer patients [16,30].
The transcriptomes of CD4+ and CD8+ TILs also uncovered potential genes and their
associated pathways, which reflect their roles in the TME. For instance, our data showed
that TGFβ1 gene encoding TGF-β, which is known to inhibit T effector cell functions,
promote Treg survival/differentiation, and support tumor invasion and metastasis [31,32],
was expressed at higher levels on CD8+ TILs compared to CD4+ TILs. It has been reported
that the expression of TGFβ1 on CD8+ TILs can modulate their antitumor functionality,
while a pharmacological blockade of TGF-β can restore their cytotoxic function [33]. More-
over, two recent reports have suggested that TGF-β blockade can efficiently prevent CRC
metastasis in tumor models and can also enhance the efficacy of PD-L1 blockade [34,35].
These findings implicate that the presence of additional immune subversive mechanisms
in the TME, apart from TGF-β release from FoxP3+ Tregs, and even tumor cells [32,36].
In a similar fashion, we found that CAECAM, which is known to act as a proangiogenic
factor supporting vascularization within the TME [37], was overexpressed in CD4+ TILs
compared to CD8+ TILs. This latter finding implicates the potential involvement of CD4+
TILs, more likely to be CD4+ Tregs, in promoting tumor angiogenesis. In contrast, CD8+
TILs showed elevated levels of inflammatory chemokine genes, CCL3 and CCL5, which
are involved in the trafficking and recruitment of other immune cell populations to hinder
tumor growth [38]. Additionally, genes encoding the IFN-γ receptor subunits IFNGR1 and
IFNGR2 were downregulated, whereas IFNG gene expression, per se, was upregulated in
CD8+ TILs. In the canonical IFN-γ signaling pathway, IFN-γ subunit binds to its receptors
and activates the antitumor immune cascade through activation of Janus kinases, JAK1
and JAK2 [39]. In this context, the downregulation of IFN-γ receptors could potentially
impair the cytotoxic function of CD8+ TILs and fail to induce appropriate antitumor re-
sponses in the CRC microenvironment. The above findings could rationalize the impact
of the identified gene signature on the function of TILs, and suggest potential immune
mechanisms and signaling pathways which could impair CD8+ TIL function within the
CRC microenvironment. It has been reported that IFNG receptor signaling is dispensable
for the expansion, contraction, and memory differentiation of CD8+ T cells [40]. More-
over, rare multiple cutaneous squamous cell carcinoma was reported in a patient with a
deficiency of IFNGR2 expression [41]. Interestingly, we found that the downregulation of
IFNGR1/R2 was associated with the upregulation of T cell exhaustion genes, including
PDCD1 and TOX, on CD8+ TILs. These data show that CD8+ T cells in the CRC TME might
be exhausted/less functional, and lose their Th1-mediated tumor elimination competency.
Additionally, we investigated the pattern of expression of methylation-related genes in
patients with high and low ppScores to examine if there are any correlations between the
expression of these epigenetic genes and the transcriptome signature of TILs. We found
that CD4+ TILs in patients with high ppScores express low DNMT3B, KDM5B/6B and high
HDAC5 and KAT2B levels, compared to those with low ppScores (data not shown). This is
consistent with previous findings showing that the DNMT3B gene was downregulated in
CD4+ TILs from CRC patients with advanced stages [15], indicating that transcriptional
silencing through DNA methylation in CD4+ TILs could be associated with poor prognosis;
KAT2B is important to skew Th1 differentiation into Tregs [42]; HDACs, including HDAC5,
could prevent the induction and differentiation of Th1 cells [43,44], and reduced levels of
KDM5B and KDM6B can positively skew Th2 differentiation [45,46]. However, IFN-γ and
their receptor expression in CD8+ T cells may also be influenced by epigenetic modifica-
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tions [47] and, therefore, functional investigations are necessitated to confirm impaired
IFN-γ release by CD8+ TILs in CRC patients.
Aligning the top deregulated genes in CD4+ TILs with TCGA led us to identify a
unique poor prognosis gene signature associated with reduced DSS in CRC patients. We
found that this gene signature is an independent prognostic indicator, independent of
demographic features of CRC patients. Importantly, this gene signature corresponded with
clinical staging, as a high ppScore was mainly present in CRC patients with advanced stage
disease. Moreover, we found that patients with high and low ppScores presented with a
distinct gene profile, as evident from the hierarchical clustering of genes.
Next, we investigated the differences in T cell infiltration between CRC patients
with low and high ppScores. Oure data revealed that patients with a high ppScore had
significantly lower infiltration of CD4+ TILs. These results prompted us to investigate
the different T cell subsets in the TME of patients with high and low ppScores. We
found that genes related to Treg, Th1, and Th17 cells were highly expressed in patients
with a low ppScore, while Th2-related genes were highly expressed in patients with
a high ppScore. These data reflect that CRC patients with poor prognosis have less
Treg, Th1 and Th17 infiltration, while patients with better prognosis have higher levels
of these cells in the TME but reduced levels of Th2 cells. Th1 cells are crucial for the
proliferation of CTLs, and Th1 cytokines inhibit the generation of Th2 [48]. Thus, lower
Th1 cells in patients with a high ppScore may consequently lead to increased Th2 cells
in these patients, as reported in this study. Moreover, as mentioned above, elevated
FoxP3+ Treg levels in the TME have been associated with favorable prognosis in CRC
patients [8]. In addition, Th1 levels have also been shown to be strongly associated with
improved prognosis in CRC patients [49]. However, Th17 cell levels have been shown to
be involved in pro- and antitumor roles [50], and evidences have been provided on their
negative influence on disease prognosis in CRC patients [51]. The combined effects of
these preferential accumulations of different T cell subsets lead to a reduction in immune
cell response, T cell activation/chemotaxis, and other critical antitumor immune response-
related pathways in patients with high ppScores, indicating a potential contribution to
worsened disease outcomes in these patients. Moreover, we found that genes related to
the negative regulation of apoptosis were upregulated in CD4+ TILs, compared with CD8+
TILs in patients with a high ppScore. This upregulation of antiapoptotic genes could lead
to increase in levels of CD4+ TILs and shift the balance between Th cells and CTLs in the
TME, which favors tumor progression [52]. It has been reported that targeted elimination
of tumor cells by CTLs is mediated by the stimulation of apoptosis cascade through the
perforin/granzyme pathway [53]. Here, we found that expression levels of GRZMA and
PRF1 genes were lower in patients with a high ppScore compared to patients with a low
ppScore, potentially suggesting the suppression of CTLs in these patients and implicating
that the identified gene signature could be utilized as a potential predictive prognostic
biomarker in CRC patients.
Importantly, we found genes related to DNA replication, damage and repair were
also downregulated in patients with high ppScore. These results bear significance due
to the relevance of genomic instability and disease outcomes in CRC patients. CRC
patients with hypermutated tumors exhibiting deficiency in the DNA mismatch–repair
system and microsatellite instability respond well to immunotherapy [54]. Therefore, the
poor prognostic gene signature identified in this study could have important potential
clinical implications.
4.1. Limitations and Future Directions
In this study, we performed transcriptomic analyses of CD4+ and CD8+ TILs from
a relatively small cohort of CRC patients. Additionally, limitations associated with RNA
amplification and RNA-Seq analyses could lead to potential bias [55], which cannot be
fully neglected, and confirmatory flow cytometric analyses would endorse these findings.
Importantly, these data could be further strengthened by performing functional analyses on
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CD4+ TILs considering pathways, such as TNF-signaling and IL-1-mediated signaling/co-
stimulation pathways, which were upregulated in these cells. Functional studies would
also ascertain the impact of downregulated genes on the functional capacity of CD8+
TILs in eliciting potent antitumor immune responses. CD4+ T cell subsets, which are
indeed responsible for prognostic differences, could also be explored further in a similar
approach. In addition, detailed immune cell profiling using flow cytometry, coupled
with single-cell RNA-Seq analyses from whole tumors, would assist in a comprehensive
categorization of TILs present within the TME; this is particularly helpful in determining
the level of tumor immunogenicity and predicting the host immune response to certain
cancer immunotherapy. Moreover, quantifying different subsets of TILs and correlating the
results with the upregulation of our identified gene signature would rule out the possible
impact of CD4+ vs. CD8+ T cell numbers (CD4+:CD8+ ratio) in the TME. Lastly, in addition
to TCGA datasets, the identified gene signature could be further validated in samples
from larger cohorts of CRC patients and with varying disease stages, and RT-qPCR gene
expression analysis could be employed to validate the identified gene signature in CRC
tumor samples.
4.2. Conclusions
Our findings extend knowledge on the potential roles of CD4+ and CD8+ TILs in CRC
patients. The differentially regulated genes and their associated pathways reflect how these
cells could contribute to CRC progression. However, functional studies are required to
ascertain the precise roles of these cells. We identified that a high Th2 gene signature and
a low Treg/Th1/Th17 gene signature in patients with a high ppScore is associated with
poor DSS. This identified gene signature takes into consideration multiple parameters in
assessing disease prognosis since it is not linked to TNM staging, but it is based on the
identification of dysregulated genes in TILs from CRC patients. Therefore, the ppScore
can potentially be utilized as an additional prognostic indicator engulfed within precision
medicine protocols. However, further validations should strengthen its clinical significance.
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